The global subcutaneous biologics market is rising due to growing demand for patient-friendly self-administrable therapies and the shift toward biologic drugs with targeted mechanisms of action. The ...

aDepartment of Medicine ‘B’, Sheba Medical Center, Ramat Gan, Israel Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been increasingly ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-monthly injection of Eli Lilly’s Omvoh for maintenance therapy in adult patients ...

“With today's approval, guselkumab is the first IL-23 inhibitor to offer inflammatory bowel disease patients robust clinical and endoscopic results with a fully subcutaneous induction dose regimen, ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

AstraZeneca PLC (NASDAQ:AZN) announced Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of ...

AstraZeneca has announced that Saphnelo (anifrolumab) has been recommended for approval in the European Union (EU) as a self-administered once-weekly pre-filled pen for adult patients with systemic ...